What question did this study set out to answer?

To determine whether adding sequential preoperative or postoperative docetaxel to preoperative doxorubicin and cyclophosphamide improves response rates, disease-free survival, and overall survival in operable breast cancer.

April 11, 2006Journal of Clinical OncologyOpen Access

Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

View Full Paper

Ask AI

Bookmark

Authors

HBHarry D. BearVirginia Commonwealth University SAStewart AndersonUniversity of Pittsburgh RSRoy E. SmithShadyside Hospital

Discussion

Member takes

Implication

Randomized trial finds adding docetaxel to preoperative chemotherapy reduces local recurrence in operable breast cancer, indicating subset benefits despite no overall survival gain.

Key Points

To determine whether adding sequential preoperative or postoperative docetaxel to preoperative doxorubicin and cyclophosphamide improves response rates, disease-free survival, and overall survival in operable breast cancer.
Randomized trial (NSABP Protocol B-27) enrolling 2,411 women with operable breast cancer assigned to preoperative doxorubicin plus cyclophosphamide (AC) followed by surgery, AC followed by docetaxel then surgery, or AC followed by surgery then docetaxel.
Tamoxifen was initiated concurrently with chemotherapy, and median follow-up was 77.9 months across 2,404 evaluable patients.
Addition of docetaxel to AC did not significantly impact disease-free survival or overall survival, but significantly reduced the incidence of local recurrences as first events (P = .0034).
Preoperative docetaxel significantly improved disease-free survival among patients with a clinical partial response after AC (HR = 0.71; 95% CI, 0.55 to 0.91; P = .007), whereas postoperative docetaxel did not.
Pathologic complete response doubled with preoperative docetaxel and strongly predicted overall survival regardless of treatment arm (HR = 0.33; 95% CI, 0.23 to 0.47; P < .0001).

Cite This Study

Bear et al. (2006) studied this question.

synapsesocial.com/papers/6a0cbb6dfcb0a2efa52caa51 https://doi.org/10.1200/jco.2005.04.1665

View Full Paper

Ask AI

Bookmark

April 11, 2006Journal of Clinical OncologyOpen Access

Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

View Full Paper

Ask AI

Bookmark

Authors

HBHarry D. BearVirginia Commonwealth University SAStewart AndersonUniversity of Pittsburgh RSRoy E. SmithShadyside Hospital

Discussion

Member takes

Implication

Randomized trial finds adding docetaxel to preoperative chemotherapy reduces local recurrence in operable breast cancer, indicating subset benefits despite no overall survival gain.

Key Points

To determine whether adding sequential preoperative or postoperative docetaxel to preoperative doxorubicin and cyclophosphamide improves response rates, disease-free survival, and overall survival in operable breast cancer.
Randomized trial (NSABP Protocol B-27) enrolling 2,411 women with operable breast cancer assigned to preoperative doxorubicin plus cyclophosphamide (AC) followed by surgery, AC followed by docetaxel then surgery, or AC followed by surgery then docetaxel.
Tamoxifen was initiated concurrently with chemotherapy, and median follow-up was 77.9 months across 2,404 evaluable patients.
Addition of docetaxel to AC did not significantly impact disease-free survival or overall survival, but significantly reduced the incidence of local recurrences as first events (P = .0034).
Preoperative docetaxel significantly improved disease-free survival among patients with a clinical partial response after AC (HR = 0.71; 95% CI, 0.55 to 0.91; P = .007), whereas postoperative docetaxel did not.
Pathologic complete response doubled with preoperative docetaxel and strongly predicted overall survival regardless of treatment arm (HR = 0.33; 95% CI, 0.23 to 0.47; P < .0001).

Cite This Study

Bear et al. (2006) studied this question.

synapsesocial.com/papers/6a0cbb6dfcb0a2efa52caa51 https://doi.org/10.1200/jco.2005.04.1665

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark